DIAMEDICA
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circu... lation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.
DIAMEDICA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.diamedica.com
Total Employee:
1+
Status:
Active
Contact:
(763)270-0603
Email Addresses:
[email protected]
Total Funding:
87.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-06-30 | Sanomune | Sanomune acquired by DiaMedica | N/A |
Investors List
SK Group
SK Group investment in Post-IPO Equity - DiaMedica
Fosun Pharma
Fosun Pharma investment in Post-IPO Equity - DiaMedica
Hermed Capital
Hermed Capital investment in Post-IPO Equity - DiaMedica
Genesys Venture
Genesys Venture investment in Pre Seed Round - DiaMedica
Key Employee Changes
Official Site Inspections
http://www.diamedica.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.03 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "DiaMedica"
Investor Relations :: DiaMedica Therapeutics, Inc. (DMAC)
Jul 17, 2025 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from …See details»
Press Releases :: DiaMedica Therapeutics, Inc. (DMAC)
Jul 23, 2025 DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 1 2 3 4 5 6 7 8 9 10See details»
Board of Directors :: DiaMedica Therapeutics, Inc. (DMAC)
Seasoned biopharmaceutical and health care industry executives comprise the DiaMedica Therapeutics’ board of directors.See details»
Diamedica | Safe anaesthesia and respiratory solutions
Safe anaesthesia and respiratory solutions for limited resource settings A commercial enterprise with a huge humanitarian heart.See details»
DiaMedica - Crunchbase Company Profile & Funding
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.See details»
DiaMedica Therapeutics Inc. - LinkedIn
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments …See details»
DiaMedica Therapeutics Company Profile - Craft
Oct 29, 2024 DiaMedica Therapeutics has 3 employees at their 1 location and $500 k in annual revenue in FY 2018. See insights on DiaMedica Therapeutics including office locations, …See details»
DiaMedica Therapeutics Inc. - Executive Bio, Top Executies, and ...
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.See details»
DiaMedica Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
May 7, 2025 Explore DiaMedica Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 9 clinical trials, 70 news, and 3 literature, Disease Domain:Nervous …See details»
DiaMedica Org Chart + Executive Team - The Official …
The org chart of DiaMedica contains its 25 main executives like Rick Pauls, Scott Kellen, Alex Aimetti and Aaron Olson.See details»
#DiaMedica Therapeutics Announces Closing of $30.1 Million …
Jul 24, 2025 In a robust move to bolster its financial and strategic footing, DiaMedica recently concluded a substantial $30.1 million private placement of common shares to accredited …See details»
DiaMedica Therapeutics Raises $30 Million in Private Placement to ...
Jul 21, 2025 DiaMedica has received binding commitments for participation in the private placement from certain non-management, related parties, in the aggregate amount of $30.1 …See details»
Diamedica - Crunchbase Company Profile & Funding
Diamedica SIA supplies diagnostic equipment, reagents, and support for clinical and research laboratories.See details»
DiaMedica Therapeutics Reports Second Quarter 2025 Financial …
3 days ago MINNEAPOLIS-- (BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments …See details»
Board of Directors :: DiaMedica Therapeutics, Inc. (DMAC)
Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from 2002 until 2010.See details»
About Us - Diamedica
A commercial enterprise with a huge humanitarian heart, Diamedica incorporates training and education with reliable and sustainable products to enable safe anaesthesia.See details»
DiaMedica Secures $30M Funding for First-Ever Preeclampsia …
Jul 21, 2025 $30M private placement funds groundbreaking preeclampsia treatment development through 2027. Learn how DiaMedica plans to advance first-in-class therapy. See …See details»
Breaking Ground in Biopharmaceuticals DiaMedica Therapeutics to ...
Jul 23, 2025 In an era marked by remarkable advancements in healthcare, one company is positioning itself at the forefront of biopharmaceutical innovation. DiaMedica Therapeutics Inc. …See details»
Earnings call transcript: DiaMedica Therapeutics Q2 2025 shows ...
2 days ago Full transcript - DiaMedica Therapeutics Inc (DMAC) Q2 2025: Conference Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 twenty …See details»
DiaMedica Therapeutics Provides a Business Update and …
MINNEAPOLIS, March 17, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke …See details»